Century Therapeutics, Inc. (IPSC) Misses Q3 EPS by 1c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q3 EPS of ($0.40), $0.01 worse than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Voya Financial estimates Q2 alternative investment pre-tax loss of $9M-$19M
• RBC Capital Upgrades Schott Pharma AG (1SXP:GR) to Outperform